The Future of
Drug Discovery is Here.
Axcelead accelerates the discovery and development of high-value therapeutic candidates for the preclinical stage leading to human clinical trials. We leverage our proprietary end-to-end platform to enable our biotechnology and pharmaceutical partners to deliver benefits to patients around the world.
Who We Are
Axcelead is your trusted drug discovery and development partner.
We were formed in 2017 as a Takeda spin-out with a singular vision in mind – to support healthcare innovation as the world’s most trusted drug discovery solutions provider. We bring our vision to life by harnessing our expertise and proven track record of success in small molecule, cell therapy and immune-oncology drug discovery to our partners to advance and improve their drug pipelines.
What We Do
Oncology, immunology, neuroscience drug discovery and so much more.
At Axcelead, we are focused on accelerating the discovery and development of high-value drug classes through our end-to-end platform, enabling our biotechnology and pharmaceutical partners to deliver benefit to patients around the world.
Client Outcomes
We are your trusted partner.
At Axcelead, we have an aggressive mission to become the most trusted drug development solutions provider to leading biotechnology and pharmaceutical companies. Our wealth of expertise and knowledge stems from our robust client base, with over 100 facilities including pharmaceutical companies, venture companies and academia utilizing its services.
Our current partners in the US consist of cutting-edge companies developing new and proven drug candidates and modalities for oncology, immunology and neuroscience indications.
News
Our latest news and press releases.
Research results of a mouse model of chronic kidney disease (AXCC mice) generated in Axcelead DDP has been published in the American Journal of Pathology as a co-authored article.
A novel deep learning approach for analyzing glomerular basement membrane lesions in a mouse model of X-linked...
A Co-authored Paper regarding Immunocompromised type 1 Diabetic Mini-pigs was Published in the Cell Transplantation
Xenogenic Engraftment of Human Induced Pluripotent Stem Cell–Derived Pancreatic Islet Cells in an Immunosuppressive Diabetic Göttingen Mini-pig...
Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals
September 10, 2024 - Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as...